RegBase
日本語
Official

Bayer Yakuhin, Ltd.

バイエル薬品株式会社· Corporate Number: 5120001057709

バイエル薬品株式会社は、大阪府大阪市北区梅田に本社を置く企業であり、業種は未公開である。2017年9月29日に医薬品医療機器等法および医薬品・医療機器等の品質・有効性・安全性確保に関する法律に関し、それぞれ複数の公的処分を受けている。

For developers: integration details

You do not need this for normal browsing. Use it when integrating this company record into an internal tool or AI workflow.

/api/v1/search?q=5120001057709&limit=5
Open API responseAPI docs

Public Record Summary

Actions in last 3 years
0records
Actions in last year
0records
Latest action
about 8 years ago

29 Sept 2017

Total penalties
-

Enforcement and administrative action history

医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律改善指導
Confirmed entity match

Delayed adverse effect reporting occurred for the pharmaceuticals: Xarelto, Biaaspirin (anticoagulant), Stivarga, Nexavar (anticancer drugs)

29 Sept 2017Ministry of Health, Labour and Welfare
Open source archiveCheck original source
医薬品医療機器等法報告命令
Confirmed entity match

Following the public announcement on May 26 (Friday) that there was a delay in reporting adverse reaction cases for Xarelto tablets (generic name: rivaroxaban), the Ministry of Health, Labour and Welfare conducted an investigation to determine whether there were any unreported or delayed cases for all pharmaceuticals manufactured and sold by the company, based on Article 68-10, Paragraph 1 of the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc. The company was also asked to report by July 31 (Monday) on the causes of the delays and related matters.

31 Jul 2017Ministry of Health, Labour and Welfare
Open source archiveCheck original source
医薬品医療機器等法報告命令
Confirmed entity match

Following the public disclosure on May 26 (Friday) that Bayer Yakuhin Ltd. experienced a delay in reporting 12 cases of adverse reactions related to Xarelto tablets (generic name: rivaroxaban), the Ministry of Health, Labour and Welfare is investigating whether there have been any unreported or delayed cases for all pharmaceuticals manufactured and sold by the company, based on Article 68-10, Paragraph 1 of the Pharmaceuticals and Medical Devices Act. The company is also required to report by July 31 (Monday) on the causes of delays and other relevant details.

29 May 2017Ministry of Health, Labour and Welfare
Open source archiveCheck original source

Language

日本語版を見る (Japanese)

Registry data

English name
Bayer Yakuhin, Ltd.
Japanese name
バイエル薬品株式会社
Corporate Number
5120001057709
Registered address
大阪府大阪市北区梅田２丁目４番９号
Status
Active

Note: This company may not have detailed gBizINFO data, or RegBase has not completed enrichment yet. The public sources below may contain supplemental registry information.

View on gBizINFO ↗View on National Tax Agency Corporate Number site ↗

gBizINFO: fetched 25 Apr 2026

Data sources

Breakdown by law

  • 医薬品医療機器等法
    2
  • 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律
    1

Breakdown by action type

  • 報告命令
    2
  • 改善指導
    1

About this English name

Registered English name from gBizINFO (Japanese Government corporate registry).

If this profile contains an error or your company needs to add context, please use the correction request form. Submissions are reviewed under RegBase editorial policy.

This page mechanically aggregates and structures public government disclosures and public registry data under the editorial policy. It is not legal advice, credit scoring, or a final procurement decision. Always verify against the official source pages.